Navigation Links
DATATRAK International Reports First Quarter Results for 2008
Date:5/8/2008

intellectual property rights; the Company's success in integrating its acquisition's operations into its own operations and the costs associated with maintaining and/or developing two product suites; and general economic conditions such as the rate of employment, inflation, interest rates and the condition of capital markets. This list of factors is not all-inclusive. In addition, the Company's success depends on the outcome of various strategic initiatives it has undertaken, all of which are based on assumptions made by the Company concerning trends in the clinical research market and the health care industry. The Company undertakes no obligation to update publicly or revise any forward-looking statement whether as a result of new information, future events or otherwise.

DATATRAK International, Inc. and Subsidiaries

Condensed Consolidated Balance Sheet Data

(Unaudited)

March 31, December 31,

2008 2007

Cash and investments $5,950,860 $8,514,361

Accounts receivable, net 1,395,989 1,070,688

Property & equipment, net 3,214,069 3,534,799

Deferred tax assets 1,301,700 1,399,000

Intangible assets, net 333,808 520,458

Goodwill 10,856,113 10,856,113

Other 511,102 577,792

Total assets $23,563,641 $26,473,211

Accounts payable and other current

liabilities $6,452,693 $3,971,883

Long-term liabilities 2,674,241 5,931,962

Shareholders' equity
'/>"/>

SOURCE DATATRAK International, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. DATATRAK and COResearch to Collaborate on Six Cardiac Safety Projects
2. DATATRAK(TM) Takes Clinical Trial Solutions to the Next Level With the Release of 5.0
3. Patients Treated with Risperidone Long-Acting Injection had a Significantly Longer Time to Relapse Compared to Quetiapine in International Clinical Study
4. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
5. New Research for Mechanical Support Devices in Pediatrics to Be Released at International Heart and Lung Transplant Meeting
6. International ACTEMRA Rheumatoid Arthritis Study Highlighted in The Lancet
7. UMDNJ-University Hospital in Newark to Tailor Diabetes Interventions for Low-Income and Minority Groups With Grant From the International Diabetes Federation
8. Harris Corporation Teams with Cancer Treatment Services International to Advance Oncology Treatment
9. Molecular Biometrics Hires Denny Sakkas, PhD Renowned Yale Embryologist and International Thought-Leader, as Chief Scientific Officer; Opening U.S. Research Facility
10. Steps Toward Stopping Autoimmune Disease: International Consortium Identifies Genes Linked to Lupus
11. XTL Biopharmaceuticals Presents Data Regarding its Hepatitis C Virus Small Molecule Program at Hep Dart 2007 - an International Scientific Conference on Viral Hepatitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... NEW YORK, December 16 ... the publication of GFT505 (80 mg/day),data ... 50 internationally,recognized expert scientists and clinicians ... the continuing role of generic lipid-modifying,treatments, ... which is commonly observed in patients ...
(Date:12/16/2009)... -- Verathon®, maker of BladderScan® bladder volume ... bladder volume ultrasound is now included in ... Prevention of Catheter-Associated Urinary Tract Infections (CA-UTIs). ... early November 2009, replace the previous guidelines ... guidelines are located on the Web at: ...
(Date:12/16/2009)... -- Greenway Medical Technologies, Inc. today announced that ... practice management and interoperability solution, Prime Suite® ... the annual 2009 Top 20 Best in ... report. ,, For practices having between six and ... Best in KLAS in ambulatory EMR for the ...
Breaking Medicine Technology:International, Well-Known Scientific Experts Say That New GFT505 Data Unlikely to Have the Potential to Affect the Established Role of Generic Fenofibrate and Bezafibrate in Managing Atherogenic Dyslipidemia 2International, Well-Known Scientific Experts Say That New GFT505 Data Unlikely to Have the Potential to Affect the Established Role of Generic Fenofibrate and Bezafibrate in Managing Atherogenic Dyslipidemia 3New 2009 CDC Guidelines for the Prevention of Catheter-Associated Urinary Tract Infections Include Bladder Volume Ultrasound 2New 2009 CDC Guidelines for the Prevention of Catheter-Associated Urinary Tract Infections Include Bladder Volume Ultrasound 3New 2009 CDC Guidelines for the Prevention of Catheter-Associated Urinary Tract Infections Include Bladder Volume Ultrasound 4New 2009 CDC Guidelines for the Prevention of Catheter-Associated Urinary Tract Infections Include Bladder Volume Ultrasound 5Greenway Medical Technologies' PrimeSuite Wins Three Best in KLAS Awards 2Greenway Medical Technologies' PrimeSuite Wins Three Best in KLAS Awards 3Greenway Medical Technologies' PrimeSuite Wins Three Best in KLAS Awards 4Survey Results Show Long Term Care Providers Wary about Healthcare Reform 48652 1Survey Results Show Long Term Care Providers Wary about Healthcare Reform 48652 2Survey Results Show Long Term Care Providers Wary about Healthcare Reform 48652 3Study shows promise for new cancer stopping therapy 48649 1Study shows promise for new cancer stopping therapy 48649 2Study finds segregation decreases access to surgical care for minorities 48646 1Study finds segregation decreases access to surgical care for minorities 48646 2
... oil may improve gum health, ROCKPORT, Maine, ... working with dentists and their patients to study ... to inflammation and gum health., (Photo: ... Dental Association, 75% of all Americans will,develop some ...
... 12 Micromet, Inc.,(Nasdaq: MITI ), a ... of cancer, inflammation and autoimmune,diseases, today announced the ... new class of antibodies that recruit T cells" ... are designed to activate,the body,s T cells to ...
Other Medicine Technology:Maine Natural Health Company Conducts Dental Clinical Trial 2Micromet Announces the Publication of BiTE Antibody Review in Drugs of the Future 2Micromet Announces the Publication of BiTE Antibody Review in Drugs of the Future 3Micromet Announces the Publication of BiTE Antibody Review in Drugs of the Future 4Micromet Announces the Publication of BiTE Antibody Review in Drugs of the Future 5
(Date:12/17/2009)... one-in-three American adults who serve as a family caregiver , ... ... Alliance on Mental Illness (NAMI) praises a new report, Caregiving ... the nearly one-in-three American adults who serve as a family caregiver. ... chosen at random and offers a national profile of people caring ...
(Date:12/17/2009)... natural relief prior to considering drugs. , ... ... D-Psoria products are the first topical, non-prescription cosmeceuticals ... skin conditions . Developed by Astrel Genome Ltd., D-Psoria ... Pharmaceuticals, St. Louis, Missouri., , ,D-Psoria products were developed in ...
(Date:12/17/2009)... provide Baptist with on-going Healthcare Cost/Risk Analysis reports, activity measures ... improvements as it translates toward reduced claim costs and positive ... , ... Jacksonville, FL (PRWEB) ... risk management company specializing in clinical/claims based cost risk analysis ...
(Date:12/17/2009)... Children’s Hospital from nearby hot tub company helps raise money ... ... Salt Lake City, UT (PRWEB) December ... the donation of a Bullfrog Spa to aid in fund ... City, Utah. Primary Children’s Medical Center, serving child patients from ...
(Date:12/16/2009)... AUSTIN, Texas, Dec. 16 Austin,s Custom ... eco-friendly countertops, co-sponsored, with Ryan Gray and Hill Country ... 219 West on Wednesday, December 9th. Fifty people showed ... ate their way through platefuls of sliders in support ... ,, What started as a casual bet over who ...
Breaking Medicine News(10 mins):Health News:NAMI Applauds New Report on Caregiving 2Health News:NAMI Applauds New Report on Caregiving 3Health News:Introducing D-Psoria, the First Cosmeceutical Products for the Relief of the Redness, Scaling, and Flaking of Severely Damaged Skin 2Health News:Introducing D-Psoria, the First Cosmeceutical Products for the Relief of the Redness, Scaling, and Flaking of Severely Damaged Skin 3Health News:Introducing D-Psoria, the First Cosmeceutical Products for the Relief of the Redness, Scaling, and Flaking of Severely Damaged Skin 4Health News:Baptist Health System Selects HealthScreen Disease Management for Employee Health Management Services 2Health News:Bullfrog Spas Helps Critically Ill Children 2Health News:Bullfrog Spas Helps Critically Ill Children 3Health News:Bullfrog Spas Helps Critically Ill Children 4Health News:Austin-Based Business Co-Sponsors Gastric Feat for Charity 2
... and Drug Administration (FDA) approves new cancer fighting drugs ... non-approved, or off-label, treatments. When the studies show promise ... these drugs to patients. By some estimates, nearly 20 ... are for off-label use. Oncologists prescribe cancer drugs off-label ...
... be Driven by Drugs from Eli Lilly/Daiichi Sankyo, AstraZeneca, ... ResourcesWALTHAM, Mass., March 24 Decision Resources, one of ... and healthcare issues, finds that, despite the patent expiries ... launches will drive an increase of $4.6 billion in ...
... average selling prices to be affected into 2010, ... According to Millennium Research Group,s (MRG,s) US ... arthroplasty implants (shoulder, elbow, digit, ankle, and wrist) ... double-digit market growth seen in recent years will ...
... Pharmaceuticals, a privately held, specialty pharmaceutical company which ... the launch of Scalacort(TM) DK (defence kit), that ... kit.Scalacort DK includes Scalacort (hydrocortisone lotion USP) 2%, ... base. Scalacort relieves itching and inflammation of the ...
... HILLS, Calif., March 24 Regal International, Inc., ... ) has been appointed by EMK Products, LLC ... PLACENTAL(R) Skin Care Product line. Under the agreement, ... distributorship for the development and management of internet ...
... 24 The Arizona Attorney General,s Office has ... student-led nonprofit Live Action released videos with undercover ... The footage shows two Planned Parenthood clinics in ... disregarding mandatory reporting laws for sexual abuse, and ...
Other Medicine News:Health News:IROs Help Decide Medically on Approved Uses of Off-Label Drugs for Cancer 2Health News:IROs Help Decide Medically on Approved Uses of Off-Label Drugs for Cancer 3Health News:Despite Patent Expiries of Leading Therapies, New Product Launches Will Drive a $4.6 Billion Increase in the Coronary Heart Disease Market 2Health News:Job Loss Means Fewer Americans Have Health Care Coverage: How Will the Economic Downturn Affect the Small-Joint Implant Market? 2Health News:Avidas(TM) Pharmaceuticals Introduces Scalacort(TM) DK Which Offers Three Scalp Solutions in One Patient Convenience Kit 2Health News:Avidas(TM) Pharmaceuticals Introduces Scalacort(TM) DK Which Offers Three Scalp Solutions in One Patient Convenience Kit 3Health News:EMK Placental Appoints Beauty Beverly Hills for Exclusive Distributorship. 2Health News:EMK Placental Appoints Beauty Beverly Hills for Exclusive Distributorship. 3Health News:Arizona Attorney General to Investigate Sexual Abuse Cover Up at Planned Parenthood Clinics 2
... The Accommodating Intraocular Lens is for the treatment ... in many middle aged and older patients. , ... in the natural lens of the eye as ... less elastic. With less elasticity, the eye has ...
Designed with your input, the ATS Simulus™ flexible annuloplasty ring and band are easy endings to complex mitral valve repairs....
The Victory single- and dual-chamber rate-responsive pacemakers from St. Jude Medical are advanced-feature systems, designed to save valuable clinic time, maximize patient safety, and provide other t...
... patient, right for the not-so-typical patient. , ... the ability to address the atypical situations ... themeven after implant. St. Jude Medical ICDs ... prepared in almost any situation, from high ...
Medicine Products: